Norman B. Gaylis

NORMAN B. GAYLIS, M.D., F.A.C.P., F.A.C.R

Norman B. Gaylis is recognized as one of the country’s leaders in the field of arthritis and rheumatic diseases. He is board-certified in Internal Medicine and Rheumatology and has been a practicing Rheumatologist in the greater Miami area for more than 35 years. Dr. Gaylis was born in Johannesburg, South Africa and completed his training as a rheumatologist at the University of Miami where he served on the clinical faculty for many years. Dr. Gaylis has presented numerous scientific papers and has conducted medical meetings around the United States and internationally. He is the author of multiple peer-reviewed articles, in particular on the subjects of rheumatoid arthritis, magnetic resonance imaging in rheumatology and other rheumatic disorders.

In addition to his clinical practice, he is the past medical director for the Rheumatology division at Cardinal Health and is a speaker and consultant for numerous pharmaceutical companies. Dr. Gaylis is the owner and chief operating officer of AARDS Research, Inc., a clinical research organization specializing in clinical research trials for autoimmune diseases and the Medial Director of Infusion and Immunotherapy Center of South Florida (IIC.) He has been a Principal Investigator in over 200 clinical trials for new pharmaceutical products for the treatment of Rheumatoid Arthritis, Osteoarthritis, Osteoporosis, Systemic Lupus, Lupus Nephritis, Gout, and Sjogren’s syndrome.

The recipient of many awards and honors, Dr. Gaylis is an active member of the American College of Rheumatology and has served on a number of committees for the organization.

Currently, he is an active member of the Rheumatology Research Foundation. As part of his commitment to clinical research, he has recently established an endowment (Norman B Gaylis, MD Research Award for Rheumatologists in Community Practice) for the Rheumatology Research Foundation to award annually for the exclusive support of research by rheumatologists in clinical practice. He strongly believes in the benefits of clinical research breaking the ground for new treatments and the viability of rheumatologists in the future of healthcare.

He is one of the founders and is a Past President of the International Society for Musculoskeletal Imaging in Rheumatology (ISEMIR). He is also past president of the Florida Society of Rheumatology.

He has been featured in the Wall Street Journal, on multiple television news shows, and for many years was also the host of HEALTH TALK, a medical talk show on the radio in South Florida. He is also on the Editorial Board of Rheumatology News

Medical School:

University of Witwatersrand

Johannesburg, South Africa
(6 year program) 1967 – 1973


Postgraduate:

Clinical: University of Witwatersrand Rotating Internship 1974 – Surgery, Orthopedics, Internal Medicine. Medical Registrar, Johannesburg General Hospital 1975 – 6 months.

Non-Clinical: Pathology Registrar at South African Institute for Medical Research 1975 – 6 months.

United Kingdom: Medical House Officer at Guys Hospital and Harley Street Clinic 1976 – 6 months.


United States:

Internal Medicine Residency at Mt. Sinai Medical Center, Miami Beach, Florida
Residency, June 30-1976 – June 30, 1977
Chief Medical Resident, July 1, 1978 –
June 30, 1979


Fellowship:

Department of Rheumatology, University of Miami Medical School, Miami, Florida,
July 1, 1979 – June 30, 1981


Current Clinical Practice:

Arthritis and Rheumatic Disease Specialties
Private Practice of Rheumatology, June 30, 1981 – Present

AARDS Research, Inc., Arthritis & Rheumatic Disease Specialties, Research Medical Director and Primary Investigator, April 2010-present

Infusion and Immunotherapy Center of South Florida (IIC), Medical Director September, 2014-present


Business Experience:

Chief Medical Officer, Hygea HealthCare 2016-present

Medical Director Rheumatology, Cardinal HealthSpecialty Solutions 2010-2013

Chief Operating Officer of Rheumatology Physicians Practice Division, Sheridan Healthcare 1992

Chief Operating Officer of Rheumatology,
Continucare Corporation 1996 – 1999

Founder and Director of Miami Arthritis Center 1985-1999


Academic and Educational Appointments :

  • Board of Directors ICAMRL 2012-2016
  • Editorial Board, Rheumatology News 2008-Present
  • American College of Rheumatology Research and Education Foundation 2006-2010
  • President of International Society for Musculoskeletal Imaging in Rheumatology(ISEMIR) 2008-2010
  • Program Chair for International Society for Musculoskeletal Imaging in Rheumatology(ISEMIR) 2007-2010
  • Clinical Associate Professor of Medicine Department of Rheumatology University of Miami, 1992 – 2002
  • President Florida Society of Rheumatology, 1992, 1994
  • Physician Ad. Committee Medicare BCBS-Florida 1992 – 1994
  • Program Chairman – Florida Society of Rheumatology, 1989 – 1991
  • Executive Member of Committee of Rheumatologic
    Care, American College of Rheumatology, 1986-
    1990
  • Member of Marketing Committee of American College of Rheumatology, 1987 – 1989
  • Florida Representative on American College of Rheumatology Committee of Rheumatologic Care1985, 1986 and 1987
  • Fellow American College of Physicians, 1984


Certifications:

American Board of Internal Medicine 1979 No.73208.

American Board of Rheumatology November 1983 ME31090.

Technical Competency in DXA Bone Densitometry 1/2003

ECFMG 1972 No. 20098274.

Flex 1978 No. 192529.


Meetings:

*active participant

  • *2015 ACR/ARHP San Francisco, CA
  • *2014 ISEMIR Santa Monica CA
  • *2013 ACR/ARHP, San Diego, CA
  • *2013 EULAR Madrid, Spain
  • *2012 November ACR Washington, D.C.
  • *2012 June International Society for Musculoskeletal Imaging in Rheumatology (ISEMIR).
  • *2011 November ACR, Chicago, IL
  • *2011 May EULAR, London, England
  • *2010 NovemberACR/ARHPScientific Meeting, Atlanta, GA
  • *2010 June 16- 19 EULAR – Rome, Italy
  • *2009 ACR, Philadelphia, PA
  • *2008 ACR, San Francisco, CA
  • *2008 EULAR Paris, France
  • *ISEMIR (International Society for Musculoskeletal Imaging in Rheumatology.) April 10, 2008, Chicago, IL 2007 EULAR – Barcelona, Spain
  • *JCR Congress of Rheumatology 2007, International Rheumatology Symposium, Pacifico Yokohama, Japan
  • *JCR Congress of Rheumatology 2006, International Rheumatology Symposium, Nagasaki, Japan
  • *2006 EULAR – Amsterdam, Netherlands
  • *2005 ACR San Diego, CA
  • *2005 EULAR – Vienna, Austria
  • *Japanese Congress of Rheumatology 2005, InternationalRheumatologySymposium, Pacifico Yokohama, Japan
  • *Rheumatology of the Future- NACE- University of Massachusetts 2005, 2006 Multiple locations in USA
  • *2004 ACR – San Antonio, TX
  • *2004 EULAR – Berlin, Germany
  • *2003 International Rheumatology Meeting- Dublin,IR
  • *2003 ACR – Orlando, FL, MRI Rheumatology
  • *1997 Arthritis Foundation, Florida Chapter: Lecture Physicians’ Practice Management
  • *1996 A.C.R. Annual Meeting – Orlando, Fl
  • *1993 August: University of Miami Postgraduate Courseon Advances in Internal Medicine – Lecture Topic: Vasculitis
  • *1991 October: University of Miami Postgraduate Courseon Advances in Internal Medicine – Lecture Topic:Vasculitis
  • *1990 October: University of Miami Postgraduate Course Postgraduate Course – Lecture Topic: Vasculitis and Sjogren’s Syndrome
  • *1989 October: University of Miami Postgraduate Courseon Advances in Internal Medicine – Lecture Topic:Vasculitis
  • *1988 American College of Rheumatology – Annual Meeting Cincinnati, OH
  • *1988 August: University of Miami Postgraduate Courseon Advances in Internal Medicine – Lecture Topic: Soft Tissue Rheumatism
  • *1988 American Rheumatism Association NationalMeeting, Houston, TX
  • **1987 American Rheumatism Association National Meeting, Washington, D.C.
  • *1987 February: Lecturer – CME Course: Association for Continuing Education, Colorado
  • *1987 October: University of Miami, Postgraduate Course in Advances in Internal Medicine – Lecture Topic: Vasculitis
  • *1986 October: University of Miami, Postgraduate Course on Advances in Internal Medicine – Lecture Topic: Vasculitis
  • *1985 December: Annual Southeastern Meeting, American Rheumatism Association, Savannah, GA
  • *1985 May: University of Miami, Postgraduate Courses on Advances in Internal Medicine, Faculty, Bal Harbour, Florida Lectures given on Infectious Arthritis and Vasculitis
  • *1985 May: Florida Academy of Family Physicians, Hollywood, Florida
  • *1984 December: Annual Southeastern Meeting of American Rheumatism Association, Baltimore, M.D
  • *1984 October: Lecturer – American Academy of FamilyPhysicians, Kansas City, MO
  • *1984 February: Lecturer – CME Course: Association for Continuation Education, CO
  • 1984, January: New Horizons Pediatric Rheumatology, Houston, TX
  • 1982 October: Review Course Rheumatology – Cook County School of Medicine, Chicago, IL
  • 1982 Symposium on Oral Gold Therapy – Sponsored by theUniversity of Miami Medical School
  • *1981 Annual Southeastern Meeting of American Rheumatism Association, Birmingham, Alabama
  • *1981 International Rheumatology MeetingParis, France
  • *1981 American Rheumatism Association, National Meeting, Boston, MA
  • 1980 Annual Southeastern Meeting of AmericanRheumatism Association, Charleston, SC
  • *1979 Advances in Internal MedicineCommending 1979)U.S.C.F., San Francisco, CA


Publications and Presentations:

PRO Assessment of Rheumatoid Arthritis Patients Experience With IV Administered Biologic Therapy. ACR/AHRP San Francisco, CA 2015.

Interim Analysis: The Effect of Adrenocorticotrophin Gel (HP Acthar Gel) in Combination with Methotrexate in Newly Diagnosed Rheumatoid Arthritis Patients from a Clinical and Structural Perspective. ACR/AHRP, San Francisco, CA 2015.

Covergent Validity of New Disease Assessment Instruments in Systemic Lupus Erythematosus in Relation to SLEDAI-2K. ACR/AHRP, San Francisco, CA 2015.

Safety of Infusing Rituximab. BMC Musculoskeletal Disorders, 2014

The Value of Magnetic Resonance Imaging. Journal of Clinical Rheumatology Volume 00, Number 00, June 2014

IM 101-006 BMS Assessment of Structural Benefits Of Abatacept as Measured by Low Field MRI n Patients with Rheumatoid Arthritis Who Have failed Prior TNF Therapy and Correlated with Clinical Outcomes as Measured by an Automated DAS 28 Scoring System 2010-2013 27 patients

Results from the RATE-RA Study: A Multicenter, Single-Arm Study to Evaluate the Safety of Administering Rituximab at a More Rapid Infusion Rate in Patients with Rheumatoid Arthritis. ACR/AHRP San Diego, October 2013.

Magnetic Resonance Imaging May Be Helpful in Predicting Long Term Efficacy of Certolizumab Pegol in Patients with Active Rheumatoid Arthritis.
EULAR, Madrid, Spain June 2013

Results from the Rate – RA Study. A Multicenter Open-Label, Single-Arm Study to Evaluate the Safety of Administering Rituximab at a More Rapid Infusion Rate in Patients with Rheumatoid Arthritis.
EULAR, Madrid, Spain June 2013

Five-Year Safety and Efficacy of Golimumab in Patients with Active Rheumatoid Arthritis Despite Previous Anti-Tumor Necrosis Factor Therapy: Final Study Results of the Phase 3, Randomized, Placebo-Controlled Go-After Trial
EULAR, Madrid, Spain June 2013

Key Changes in Health Care. Rheumatology Advisory Board Meeting, March 2013

5th Annual Int’l Society Musculoskeletal Imaging. Volume 42, Number 4, February 2013

Evaluating Joint-Space Narrowing and Cartilage Loss in Rheumatoid Arthritis by Using MRI. Arthritis Research Therapy, May 2012.

Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomized, double-blind, placebo-controlled GO-AFTER study through week 160. Ann Rheum Disease January 2012

Long-term Follow-Up of an HIV infected patient with Reactive Arthritis Treated with Infliximab. Journal of Clinical Rheumatology April 2012.

Magnetic Resonance Imaging in Rheumatoid Arthritis Clinical Trials: Emerging Patterns Based on Recent Experience. The Journal of Rheumatology, October 2011.

Golimumab Administered Subcutaneously Every Four Weeks in Patients with Active Rheumatoid Arthritis Who Were Previously Treated with Anti-TNF Agent(s): Efficacy Results of the Randomized Double-Blind, Placebo-Controlled, Go-After Study Through Week 160 EULAR, London, England May 2011

Comparison of 1.5T Whole-Body MRI and 0.2T Extremity MRI for Monitoring Rheumatoid Arthritis in a Multi-Site Clinical Trial (IMPRESS) EULAR, London, England, May 2011

Both High and Low Field MRI Correlate With Clinical Assessments and Biomarkers in Patients With Active Moderate to Severe Rheumatoid Arthritis EULAR , London, England 2011

Computer Assisted Patient Reported (PR) Versus Physician Generated (PG) Joint Count (JC) and DAS28
Scores for Rheumatoid Arthritis (RA) Patients, ACR/ACHP Scientific Meeting, Atlanta, GA, November 2010

Golimumab in Rheumatoid Arthritis Patients Previously Treated with Anti-TNF Alpha Agents: 2 Year Results from Go-After Study, EULAR, Rome, Italy, June 2010

Monitoring Joint-Space Narrowing in Rheumatoid Arthritis with 1.5T Whole Body MRI and 0.2T Extremity MRI in a Multi-Site Clinical Trial: IMPRESS, EULAR, Rome, Italy, June 2010

MRI Findings Correlate with Clinical Assessments and Biomarkers in Patients with Active Moderate or Severe Rheumatoid Arthritis, EULAR, Rome, Italy, June 2010

Retreatment with Rituximab Based on a Treatment to Target Approach Provides Better Disease Control than Treatment as Needed in Patients with RA, EULAR, Rome, Italy, June 2010

A Pilot Study of 10 Patients Measuring High and Low Field MRI Findings and Clinical Outcomes on Patients with Rheumatoid Arthritis Treated with Abatacept, EULAR, Rome, Italy June 2010

Efficacy and Safety of Retreatment in Patients with Rheumatoid Arthritis with Previous Inadequate Response to Tumor Necrosis Factor inhibitors: Results from the SUNRISE Trial. Journal of Rheumatology, 01 March 2010.

Discriminative Power of Different Combinations of Bones and Joints for Assessing Change in Rheumatoid Arthritis with MRI: Results Based on Pooled Data from Four Multisite Clinical trials. ACR/ACHP, Atlanta, GA 2010

Retreatment with Rituximab (RTX) Based On a Treatment to Target (TT) Approach Provides Better Disease Control Than Treatment as Needed (PRN) in Patients (pts) with Rheumatoid Arthritis (RA), ACR Annual Meeting, Philadelphia, PA October 2009

Golimumab in Patients with Active Rheumatoid Arthritis After Treatment with Tumour Necrosis Factor α Inhibitors (GO-AFTER Study); A Multicentre, October 2009

Strategies For Improving Treatment Outcomes, October 2009

Randomised, Double-Blind, Placebo-Controlled, Phase III Trial. The Lancet, June 2009.

In-Office Magnetic Resonance Imaging to Monitor Responses to Therapy in Rheumatoid Arthritis, Rheumatology International, Volume 30, No. 2, April 2009.

Golimumab in Rheumatoid Arthritis Patients Previously Treated with Anti-TNFα Agents (GO-AFTER Study): Week 52 Results, ACR Annual Meeting, Philadelphia, PA 2009

Evaluating Osteitis in Rheumatoid Arthritis with Gadolinium-enhanced MRI. ACR, San Francisco, CA 2008

Golimumab, a Human Anti-TNFα Monoclonal Antibody, Injected Every 4 Weeks: Efficacy & Safety in RA Patients Previously Treated with Anti-TNFα Agents (GO-AFTER Study). ACR, San Francisco, CA 2008

Adding Extremity MRI to Your Practice. Rheumatology News. Volume 8, Number 8, August 2008

Efficacy, Safety, And Dose Frequency Of Retreatment With Rituximab in RA: Results From A Randomized Controlled Trial (SUNRISE) ACR, San Franciso, CA 2008

Rheumatology And Infusion Therapy: Practice and Treatment Choices in the New Era, A Series of

Interactive CME Discussions The Foundation for Better Health Care (FBHC), 2007

Image of the Month. Rheumatology News, Volume 6, No.12, December 2007

Image of the Month. Rheumatology News, Volume 6, No. 10., October 2007

Extremity Imaging Improves RA Care. Rheumatology News, Volume 6, No. 9., September 2007

Comparison of In-office MRI Versus Conventional Radiography in Detecting Changes in Erosions After One Year of Infliximab Therapy in Patients With Rheumatoid Arthritis, Modern Rheumatology, the Journal of the Japan College of Rheumatology Mod Rheumatol (2007) 17:273-278, DOI 10.1007/s10165-007-0591-x

Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study, Ann Rheum Dis 2007;doi:10.1136/ard.2006.068304

Inflammatory, B Cartilage markers correlated with Efficacy, EULAR, Amsterdam, Netherlands 2006

Open, Randomized Study of Rheumatoid Arthritis Patients switched from Etanercept: Changes in Serum

Adalimumab Efficacy in Psoriatic Arthritis Patients Oligoarticular Arthritis: Sub analysis of Adept, EULAR, Amsterdam, Netherlands 2006

Comparison of Two Different In-Office 0.2T Magnetic Imaging Systems and Standard Radiographs in an Outpatient Rheumatoid Arthritis Patient Population, EULAR, Amsterdam, Netherlands 2006

Infliximab Provides Additional Clinical and Radiographic Benefits in RA Patients Who Have an Inadequate Response to Etanercept, EULAR, Vienna, Austria 2005

Changes in Erosive Status Detected on In-Office MRI after One Year Follow-up of Rheumatoid Arthritis Patients on Infliximab Therapy, EULAR, Vienna, Austria 2005

Comparison of In-Office MRI Versus Conventional Radiography In Detecting Changes In Erosions after One Year Follow-up Exams in Rheumatoid Arthritis Patients on Infliximab Therapy, EULAR, Vienna, Austria 2005

Effects of Cycloxygenase-2 (COX-2) Selective Inhibitor Non-steroidal Anti-Inflammatory Agents on Bone Mineral Density, ISCD, New Orleans, 2005

Rheumatoid Arthritis the Present and the Future Pacifico Yokohama, Japan 2005

JCR Congress of Rheumatology, Guest Speaker

Discontinuation of Corticosteroids Following Initiation of Infliximab in Patients with Refractory Rheumatoid Arthritis, EULAR, Berlin, Germany, 2004

Use of In-office MRI in the Evaluation of Patients With Rheumatoid Arthritis in Infliximab Therapy, EULAR, Berlin, Germany 2004

Infliximab in the Treatment of an HIV Positive Patient with Reiter’s Syndrome – Journal of Rheumatology 2003; 30-2, Pages 407-411

The Many Facets of Rheumatoid Disease . A.L.M. Plus, Page 10 Newsletter Library, March 1988

Initial Evaluation of the Arthritis Patient Postgraduate Medicine, Vol. 80, No. 50, October, 1986

An Evaluation Tool for the Diagnosis and Management of Arthritis Disorders – The Continuum of Arthritis: A Complete Approach to Treatment, 1985

The Select Value of Computer Assisted Tomography of the Brain in Cerebritis due to S.L.E., J. Rheumatol, 9:6 1982

Pulmonary Infiltration in S.L.E. – Various Causes. Workshops in Rheumatology, Vol. 3, No. 5, 1982

Uncommon Causes of Septic Arthritis in S.L.E. – Rheumatology News, March, 1981

Arthritis in S.L.E., Question and Answer Format Workshops in Rheumatology, Vol. 2, No. 2, 1981

Bacterial Monarthritis Due to Neisseria Meningitides in S.L.E.,J. Rheumatol, 8:1 1981

Ongoing Study of Salivation Induced with Salivator in Sjogren’s Patients with Xerostomia – American Rheumatism Association National Meeting, Washington, D.C

Dermatomyositis and Atypical Mycobacteria Terrae Presenting as a Class Tenosynovitis, American Rheumatism Association December 1985, Savannah, GA

Induction of Saliva in Patients with Xerostomia, Secondary to Sjogren’s Syndrome, with Aide of a Salivator. Southeastern American Rheumatism Association.December 1985, Savannah, GA.

Comparison of Oral and Intramuscular Low Dose Methotrexate, International League of Rheumatism Meeting, May 1985, Sydney, Australia

Low Dose Pulse Methotrexate in Rheumatoid Arthritis, A Clinical Overview of 65. American Rheumatism Association Southeastern Meeting, 1984

Best Paper Presented – Thieves Market

S.L.E. and Immunosuppressive Therapy Complicated by StrongyloidesStercoralis, American Rheumatism Association Meeting, June 1981

Selective Values of CAT of the Brain in Cerebritis Due to S.L.E., American Rheumatology Meeting, June 1981 and International Rheumatology Meeting, June 1981.

Septic Arthritis in S.L.E., American Rheumatism Association, Southeastern Meeting, November 1980


Press Releases:
IST/ISR Primary Investigator:


Clinical Trials:

  1. Novartis, CHOICE PsA secukinumab 2016- ongoing
  2. Amgen RA Biosimilar/Infliximab 2016-ongoing
  3. Ablynx SLE ALX-0061 2016-ongoing
  4. Sandoz RA GP2017/Humira 2016-ongoing
  5. Amgen RA Biosimilar/Rituximab 2016-ongoing
  6. Pfizer OA 2016-ongoing
  7. Eli Lilly AS 2016-ongoing
  8. Gilead RA Filgotinib 2016-ongoing
  9. Novartis AS secukinumab 2015-ongoing
  10. Astra Zeneca SLE 2-15-ongoing
  11. Amgen PsA 2015- ongoing
  12. Pfizer RA Tofacitinib/MTX/Adalimumab 2014-ongoing
  13. Pfizer- RA- Infliximab-Pfizer 2014 –ongoing
  14. Amgen PsA Enbrel 2014-ongoing
  15. Roche- RA 2013- ongoing
  16. Sanofi RA-2013 -ongoing
  17. Novartis PsA- 2013- ongoing
  18. Vertex RA 2012-2013
  19. Novartis RA 2011-2014
  20. Janssen RA IL6 (no MTX)2012-ongoing
  21. Janssen RA IL6 (MTX) 2013-ongoing
  22. Genentech SLE 2010-2012
  23. GSK (BLISS) SLE 2012-ongoing
  24. UCB SLE 2012-ongoing
  25. Pfizer (oral tablet) RA 2010-ongoing
  26. BMS RA Abatacept SC RA 2010-2014
  27. Centocor RA Go Save 2010-2013
  28. UCB certolizumab AS 2010-2013
  29. UCB certolizumab PsA 2010-ongoing
  30. Roche AS-2010-2012
  31. UCB RA-2010-2012
  32. Eli Lilly RA multiple trials 2011-2013
  33. Celgene PsA 2010-2012
  34. Cephalon SLE 2010-2012
  35. Eli Lilly SLE 2011-ongoing
  36. Takeda Gout with Cardiac Risk assessment 2011- 2012
  37. Rigel/AZ RA 2008-2012
  38. Human Genome 2008 Belimumab Lupus ongoing
  39. Incyte RA (oral tablet) 2009-2010
  40. BMS Abatacept RA 2008-2010
  41. Roche MRA RA 2008-2012
  42. BMS Abatacept SC, 2008-2010
  43. UCB Certolizumab RA 2008-2011
  44. Genentech- Rituxan Lupus 2007-2010
  45. Primus 2006-OA Limbrel Knee
  46. Genentech 2007 Ocrelizumab RA 2010
  47. Centocor RA IV Golimumab 2007-2009
  48. Human Genome 2007 Belimumab Lupus
  49. TAP Febuxostat Gout 2007-2008
  50. Amgen Etanercept RA 2007-2008
  51. Amgen AMG 108 RA 2007
  52. Biogen BG9924 RA 2007-2009
  53. Abbott-RA Humira/MTX MRI 2007-2010
  54. Merrimack-RA alpha feta protein 2007-2008
  55. Centocor-2006-2012 RA Golimumab
  56. Savient-2006-2010 Gout Uricase Agent
  57. Novartis- OA Hip 2005-2006
  58. Celltech/UCB- CDP-870 RA 2005-2011
  59. Roche- RA-2005-2011 MRA
  60. Genentech- RA- Rituxan 2005-2012
  61. GSK- OA 2005
  62. DOV- Chronic Back Pain 2005
  63. BMS- Abatacept- Open label RA 2010
  64. Human Genome- 2005 Belimumab Lupus 2010
  65. Centocor- 2005-2012 Golimumab PsA
  66. Immunomedics- 2005-2005 SLE
  67. Human Genome Sciences – Belimumab RheumatoidArthritis 2004-2006
  68. Bristol-Myers-Squibb RA 2004-2011
  69. Sepracor –RA Insomnia 2004-2005
  70. Amgen Rheumatoid Arthritis 2003
  71. Pharmacia Rheumatoid Arthritis 2003
  72. MedImmune Rheumatoid Arthritis 2003-2005
  73. Genentech Rheumatoid Arthritis 2003-2009
  74. Human Genome Sciences Lupus Erythematosus 2003-2008
  75. TAP Gout Febuxostat 2003-2005
  76. Sanofi Shoulder Pain- 2003-2004
  77. Lilly Forteo-2003-2010
  78. Merck Cox 2 Safety 2002-2003
  79. Pharmacia Cox 2 Safety 2002
  80. Amgen Anakinra post market 2002-2003
  81. TAP Gout 2002-2004
  82. Alexion – Rheumatoid Arthritis-anti TNF 2002-2004
  83. Celecoxib – Searle – Osteoarthritis/Rheumatoid Arthritis 2000
  84. Cox-2 – Merck – Osteoarthritis Hip/Knee – 1999 – 2000
  85. Trocade – Roche – Rheumatoid Arthritis – 1999 – 2001
  86. Rofecoxib – Merck – Rheumatoid Arthritis – 1999-2000
  87. Celecoxib – Searle – Osteoarthritis/Rheumatoid Arthritis – 2000
  88. P & G – Osteoarthritis – 1999 – 2003
  89. Valdecoxib – Searle Osteoarthritis/Rheumatoid Arthritis 2000 – 2003
  90. Cox-2 – Merck – Osteoarthritis Knee – 1999 – 2000
  91. Infliximab – Centocor- Rheumatoid Arthritis Post Market 1999-2000
  92. Abbott Humira Rheumatoid Arthritis – 2000 – Ongoing
  93. Celecoxib – Searle – Osteoarthritis – 1998
  94. Celecoxib – Searle – Osteoarthritis Hip – 1997
  95. Celecoxib – Searle – Osteoarthritis Knee – 1997
  96. Celecoxib – Searle – Rheumatoid Arthritis – 1997
  97. Dry Mouth – Pharmaco – 1997
  98. Tenidap – Rheumatoid Arthritis – Pfizer – 1995-1997
  99. Salagen – Sjogren’s Syndrome – 1995 – 1996
  100. Risedronate – Osteoporosis – Proctor Gamble – 1993 – 1999
  101. Benoxaprofen – Rheumatoid Arthritis – Eli Lilly – 1979
  102. Ridaura – Methotrexate – Smith Kline Beecham – 1988
  103. Nabumetone – Smith Kline Beecham – 1991
  104. Salitron Salivary Gland Stimulation Biosonic Inc. – 1988 – 1992 Sjogren’s Study
  105. Therafectin – Quintiles – 1987
  106. Diclofenac NA – Ciba Geigy – 1984 – 1987
  107. Ridaura – Methotrexate – Smith Kline Beecham – 1980 – 1981


Organizations:

American Medical Association
American College of Physicians
American College of Rheumatology
International Society for Musculoskeletal Imaging in Rheumatology

OFFICE ADDRESS: 21097 NE 27th Court
Suite 200
Aventura, Florida 33180
Phone : (305) 652-6676
Facsimile : (305) 932-6335
WEB SITE: www.rheum-care.com
E-mail : info@rheum-care.com

Copyright © 2017 Arthritis & Rheumatic Disease Specialties | Nondiscrimination | Privacy Practices | Limited English Assistance Services